Aztreonam

Y. Vivian Tsai, Pharm.D., Edina Avdic, Pharm.D.
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

Aztreonam (parenteral) should only be used for the treatment of the following infections caused by susceptible Gram-negative bacteria:
- Complicated and uncomplicated UTI [11]
- Pneumonia[11]
- Septicemia[11]
- Skin and soft tissue infections[11]
- Intra-abdominal infections (in combination with metronidazole)[11]
- Gynecologic infections (in combination with anaerobic coverage)[11]
Aztreonam (inhalation, CAYSTON^®) should only be used to improve respiratory symptoms in CF patients at least 7 years of age with known P. aeruginosa colonization in the lungs with moderate-to-severe lung disease (FEV₁ ≥25% and ≤75%).[8]

Febrile neutropenia due to Gram-negative bacteria[10]
Meningitis due to Gram-negative bacteria[13]
Alternative therapy for treatment of Gram-negative infections in patients with severe penicillin allergies.[4]
Combination therapy with ceftazidime/avibactam to treat resistant Gram-negative infections caused by metallo-β-lactamases producers and S. maltophilia. [2][3]
- As of February 2025, aztreonam is available as a combination regimen with avibactam (Emblaveo™).

There's more to see -- the rest of this topic is available only to subscribers.

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.